Abcam, Lunaphore enter co-marketing agreement for primary antibodies

Lunaphore and abcam announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET platform. The agreement will enable researchers to use abcam’s antibodies without conjugation directly on the COMET platform, with unparalleled scalability and reproducibility. By using validated primary antibodies together with the capabilities of COMET, researchers can accelerate assay development processes and achieve reliable results. The partnership also aims to address the reproducibility crisis in life sciences by providing trusted tools for multiplex immunofluorescence analysis.